Status:
COMPLETED
The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain
Lead Sponsor:
University of Rochester
Collaborating Sponsors:
United Therapeutics
Conditions:
Pulmonary Hypertension
Pulmonary Arterial Hypertension
Eligibility:
All Genders
15-80 years
Phase:
PHASE2
Brief Summary
Subcutaneous treprostinil (Remodulin) is effective therapy for pulmonary arterial hypertension, a life threatening disease of the lung blood vessels. Unfortunately, treprostinil is irritating to the s...
Eligibility Criteria
Inclusion
- Pulmonary Hypertension
- Using subcutaneous treprostinil
- Already participating as a subject in our prospective study of infusion site pain
- Has documented debilitating pain (6/10 or greater) in the study after a site change
Exclusion
- Uncontrolled hypertension
- Recent stroke or myocardial infarction
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2012
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT01260454
Start Date
November 1 2010
End Date
April 1 2012
Last Update
April 21 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mary M. Parkes Asthma Center, University of Rochester
Rochester, New York, United States, 14623